title: Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
abstract: Aggressive initial treatment of Primary Central Nervous System Lymphoma (PCNSL) has achieved prolonged survival and occasional cures. However, some patients do not respond to initial therapy and others relapse after an initial remission. The optimal salvage regimen is not known and many different strategies have been proposed. In this report we describe the efficacy of a combination of (90)Y-Ibritumomab Tiuxetan (Zevalin) and Temozolamide as a maintenance therapy for recurrent PCNS Lymphoma in two patients that are both alive and in complete remission after 9 and 10 months respectively. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
authors.affiliation: Medical Oncology (Pad. H 50 piano), University of Messina, Via Consolare Valeria, 98125, Messina, Italy. vpitini@unime.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Pitini
authors.forename: Sergio
authors.initials: S
authors.lastname: Baldari
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Altavilla
authors.forename: Carmela
authors.initials: C
authors.lastname: Arrigo
authors.forename: Claudia
authors.initials: C
authors.lastname: Naro
authors.forename: Francesca
authors.initials: F
authors.lastname: Perniciaro
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D016499:Radioimmunotherapy; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D000077204:Temozolomide; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan; D003606:Dacarbazine; D000077204:Temozolomide